

# Lithuania

Total population as of 15 April 2025 by Eurostat: 2885891

## Tuberculosis cases, 2024

### Notifications

|  |             |
|--|-------------|
| Total number of cases                                      | 666         |
| Notification rate per 100 000                              | 23.1        |
| New <sup>a</sup> and relapse                               | 650         |
| New <sup>a</sup> and relapse notification rate per 100 000 | 22.5        |
| Pulmonary  | 616 (92.5%) |
| of which microscopy-positive                               | 329 (53.4%) |
| of which laboratory-confirmed                              | 594 (96.4%) |
| Laboratory-confirmed TB cases                              | 609 (91.4%) |
| Mean age of new native TB cases                            | 51.2 years  |
| Mean age of new foreign TB cases                           | 42.5 years  |
| Foreign origin of all TB cases                             | 12 (1.8%)   |
| New (not previously treated)                               | 559 (83.9%) |

### Estimates

|  |                |
|--|----------------|
| Estimated new and relapse cases N, best [low–high] | 890 [720–1100] |
|--|----------------|

<sup>a</sup> Cases with unknown previous TB treatment history included in new cases.

## Drug resistance surveillance and TB/HIV coinfection, 2024

|  |               |
|--|---------------|
| Completeness of DRS data <sup>a</sup>  | Yes           |
| Completeness of HIV data <sup>b</sup>  | Yes           |
| Case-linked data-reporting   | Yes           |
| Cases with DST results   | 609 (100.0%)  |
| Estimated RR-TB among notified bacteriologically confirmed pulmonary TB cases N, best [low–high] | 120 [110–130] |
| Pulmonary RR/MDR-TB cases notified   | 105 (17.7%)   |
| of which pre-XDR-TB cases  | 21 (21.9%)    |
| Notified RR/MDR-TB of which pre-XDR-TB cases   | 106 (17.4%)   |
| of which pre-XDR-TB cases  | 21 (21.6%)    |
| TB cases tested for HIV  | 653 (98.0%)   |
| HIV-positive TB cases  | 15 (2.3%)     |
| of these on ART  | –             |

<sup>a</sup> National coverage 100% or >75% have DST for rifampicin.


<sup>b</sup> More than 50% of TB cases with reported HIV status.

## Treatment outcome monitoring


| Geographical coverage       | National   |                                      |
|-----------------------------|--|--------------------------------------|
| Outcome cohort <sup>a</sup> | New culture-positive pulmonary TB cases notified in 2023 | All RR/MDR-TB cases notified in 2022 |
| Case-linked data-reporting  | Yes  | –                                    |
| Cases notified              | 503  | 115                                  |
| Success                     | 359 (71.4%)  | 78 (67.8%)                           |
| Died                        | 70 (13.9%)   | 21 (18.3%)                           |
| Failed                      | 13 (2.6%)  | 1 (0.9%)                             |
| Lost to follow-up           | 11 (2.2%)  | 11 (9.6%)                            |
| Still on treatment          | 47 (9.3%)  | 4 (3.5%)                             |
| Not evaluated               | 3 (0.6%)   | 0 (0.0%)                             |

<sup>a</sup> Treatment outcome after 12 months (or 24 months).


## TB notification rates by previous treatment history, 2015–2024




## New and relapse TB cases – notification rates by age group, 2015–2024




## TB cases by geographical origin, 2015–2024




## TB/HIV coinfection, 2015–2024



## RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous treatment history among all TB cases, 2015–2024



## Treatment outcome, new culture-confirmed pulmonary TB cases, 2014–2023



<sup>a</sup> All EU/EEA country population estimates are from Eurostat [website]. Brussels: Eurostat; 2024 (<https://ec.europa.eu/eurostat/home>, accessed 25 February 2026).